C WorldWide Group Holding A S decreased its stake in Amgen, Inc. (NASDAQ:AMGN) by 3.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 110,716 shares of the medical research company’s stock after selling 4,512 shares during the period. Amgen accounts for about 0.3% of C WorldWide Group Holding A S’s holdings, making the stock its 28th biggest position. C WorldWide Group Holding A S’s holdings in Amgen were worth $20,643,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Baker Ellis Asset Management LLC purchased a new position in shares of Amgen in the third quarter worth about $108,000. Phocas Financial Corp. purchased a new position in shares of Amgen in the second quarter worth about $110,000. Jackson Grant Investment Advisers Inc. increased its stake in shares of Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares in the last quarter. Omnia Family Wealth LLC increased its stake in shares of Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares in the last quarter. Finally, Grove Bank & Trust increased its stake in shares of Amgen by 87.4% in the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after purchasing an additional 341 shares in the last quarter. 78.46% of the stock is currently owned by institutional investors and hedge funds.
Amgen, Inc. (NASDAQ AMGN) opened at $185.04 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. Amgen, Inc. has a 12 month low of $150.38 and a 12 month high of $191.10. The company has a market cap of $134,320.00, a P/E ratio of 16.72, a P/E/G ratio of 2.60 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion during the quarter, compared to analysts’ expectations of $5.75 billion. During the same quarter in the previous year, the company earned $3.02 EPS. The business’s quarterly revenue was down .7% compared to the same quarter last year. equities analysts forecast that Amgen, Inc. will post 12.71 EPS for the current year.
Amgen declared that its board has approved a share buyback program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is currently 41.55%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total value of $269,665.75. Following the completion of the transaction, the executive vice president now owns 56,106 shares of the company’s stock, valued at approximately $9,921,223.98. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. In the last three months, insiders sold 7,050 shares of company stock valued at $1,225,765. Corporate insiders own 0.19% of the company’s stock.
Several equities analysts have recently weighed in on AMGN shares. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 target price for the company in a research note on Friday, October 27th. Bank of America lifted their target price on shares of Amgen to $210.00 and gave the stock a “buy” rating in a research note on Thursday, October 5th. Barclays lifted their target price on shares of Amgen from $180.00 to $190.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. Royal Bank of Canada reduced their target price on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research note on Thursday, October 26th. Finally, Cann reaffirmed a “buy” rating and set a $203.00 price objective on shares of Amgen in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company’s stock. Amgen has a consensus rating of “Hold” and a consensus target price of $190.15.
TRADEMARK VIOLATION WARNING: “C WorldWide Group Holding A S Lowers Holdings in Amgen, Inc. (AMGN)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/13/c-worldwide-group-holding-a-s-lowers-holdings-in-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.